案件查詢
計畫主持人
研究護理師
癌別
關鍵字(計畫編碼、計畫名稱、收案條件、藥物)
計畫編碼 計畫主持人 研究護理師 癌別 計畫名稱 收案條件 藥物 附件檔
D8990C00001 鍾奇峰 翁湘芸#1677 吳星慧#1676 其他 一項模組化第 I/IIa 期、開放性、多中心試驗,評估 AZD5335 遞增劑量單一療法與合併抗癌藥物使用於實體腫瘤參與者的安全性、耐受性、藥動學和初步療效 Ovarian Cancer
Lung cancer
AZD5335 AZD5335 +AZD5305 下載
D8991C00001 鍾奇峰 楊琇帆#1689馮晴#1670 婦癌 一項隨機、開放標籤 III 期研究,比較 AZD5335 與 Mirvetuximab Soravtansine 在 FRα-high 中的療效以及 AZD5335 與醫師選擇化療上皮性卵巢癌患者中的療效 (TREVI-OC-01) 1.high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
2. must have platinum-resistant disease:
(a) Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between > 3 months and ? 6 months after the date of the last dose of platinum.
(b) Participants who have received 2 or 3 lines of platinum therapy must have progressed ? 6 months after the date of the last dose of platinum.
3. must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy
AZD5335 下載
DS7300-203 鍾奇峰 張雅雯#1687 其他 一項第 1b/2 期、泛腫瘤、開放標記試驗,旨在評估 Ifinatamab Deruxtecan (I-DXd) 用於復發性或轉移性固體腫瘤受試者的療效及安全性 (IDeate-Pantumor02) Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra.
Subjects with histological variants are allowed if urothelial histology is predominant.
Small cell/neuroendocrine tumors are not allowed even if mixed histology
Ifinaatamab Deruxtecan (I-DXd) 下載
DS8201-793 陳鵬宇 楊琇帆#1689 肺癌 一項第 3 期、多中心、隨機分配、開放標示,在患有局部晚期無法切除或轉移性 HER2 過度表現和 PD-L1 TPS <50% 非鱗狀非小細胞肺癌之參與者,評估 Trastuzumab Deruxtecan 併用 Pembrolizumab 相較於鉑類化療併用 Pembrolizumab 作為第一線療法的試驗 (DESTINY-Lung06) 非麟狀局部晚期無法切除
轉移性NSCLC
Trastuzumab Deruxtecan (T-DXd; Enhertu) 下載
DS8201-801 鍾奇峰 莊淑敏#1673 乳癌 這是一項皮下注射 T-DXd 加上玻尿酸的第 1 期、開放性、多中心、劑量調升和劑量擴展試驗,旨在評估 SC T-DXd 加上玻尿酸在轉移性實體腫瘤參與者中的安全性、耐受性、PK 和療效 Participants
‧ HER2+, HER2low as per FDA-approved T-DXd indication
‧ locally advanced/metastatic cancer
‧ No previous history of T-DXd use
T-DXd 下載